SLEEP 2026 | Individualized dosing of low-sodium oxybate for narcolepsy and idiopathic hypersomnia: DUET study

Yes, so lower sodium oxybate, it’s FDA approved for the treatment of narcolepsy and idiopathic hypersomnia at doses up to nine grams per night. And new data from the Jazz DUET study, which is a Phase IV study of lower sodium oxybate, demonstrated how patients and clinicians together can make decisions to titrate up to 12 grams per night, either in even doses or asymmetric doses for narcolepsy and for idiopathic hypersomnia. And so what we showed is that there are many combinations that healthcare providers chose by listening to the patient’s symptoms or concerns. So in other words, patients who felt that they would benefit by going higher, and we do have data supporting that higher dosing beyond nine grams improves outcomes in patients with both of these types of conditions. But perhaps patients who have to wake up early and need to be very alert in the morning might favor taking a higher dose earlier for their first dose rather than their second dose. Or patients who may have difficulty falling asleep at night might favor being on a higher dose in the first dose rather than the second dose. So these abstracts provided demonstration that there can be a lot of flexibility in deciding which patients benefit from more of an asymmetric dosing versus symmetric dosing. And with the patient’s input, we can achieve better outcomes that are very satisfying to patients.

This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.